mTOR is one of the most thoroughly studied molecular switches in ageing, with robust evidence from animal models that its inhibition extends lifespan. The translation to healthy humans has not yet been made, however: there is no large clinical study demonstrating that mTOR inhibition produces lifespan extension or health gains in humans without side effects. Anyone reading about rapamycin, curcumin, or other mTOR-targeting agents would do well to maintain the distinction between compelling animal research and proven human benefit.
mTOR (in full: mechanistic target of rapamycin) is a protein found in virtually all organisms and acts as a central switch inside the cell. It reads the availability of nutrients and growth factors and on that basis decides whether the cell should grow, produce proteins, or instead clear out its own damaged material through a process called autophagy. That clean-up process is essential for keeping cells healthy.
mTOR is not a single molecule but consists of two distinct complexes: mTORC1 and mTORC2. mTORC1 drives cell growth and metabolism and responds to the drug rapamycin. mTORC2 has different roles and is not directly affected by rapamycin. This distinction matters because therapies that inhibit only mTORC1 have different effects and side effects than agents that target both complexes.
When mTOR remains active for too long or too strongly, things go wrong. Overactivity of mTOR has been linked to accelerated ageing, cancer, diabetes, and neurodegenerative diseases such as Alzheimer's. The reverse has also been studied: in senescence, the process by which individual cells permanently stop dividing and secrete harmful substances, mTOR appears to play a directing role. If mTOR stays active while a cell temporarily pauses its division, that cell becomes senescent; if mTOR is blocked, the cell enters a manageable resting state.
The strongest evidence for the role of mTOR in ageing comes from animal research. Inhibition of mTORC1 with rapamycin extended lifespan in every model organism studied, from yeast to mammals. This is one of the most robust findings in ageing science. Whether the same effect occurs in humans has not yet been demonstrated; rapamycin is used as an immunosuppressant after organ transplantation, but large-scale research into lifespan extension in healthy people does not exist.
mTOR does not operate in isolation either. It is intertwined with other well-known ageing-related processes, such as AMPK (a kind of fuel gauge for the cell), SIRT1 (an energy sensor), the inflammation regulator NF-kB, and FOXO proteins involved in stress resistance. Exactly how all these switches interact during human ageing has not yet been fully clarified. Finally, curcumin, the active compound in turmeric, is linked in laboratory experiments with worms, fruit flies, and yeast to lifespan extension through pathways that include the mTOR pathway, but evidence in humans is entirely absent; no human benefit has been demonstrated from supplementation based on this research.
Based on seven claims covered by eight PMIDs (including mechanistic work, model-organism studies, and review literature). Strong evidence for the basic biology and the action of rapamycin in animal models; moderate evidence for the role of mTOR dysregulation in human diseases; limited evidence for the relevance of curcumin in humans.